Tests a new drug added to chemotherapy for advanced bowel cancer
Tests INCA33890 with chemotherapy and bevacizumab in adults with advanced colorectal cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Key facts
- Where
- Akashi-shi, Chiba, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kawasaki-shi, Kita-gun, Kitaadachi-gun, Kobe, Kōtoku, Kurashiki-shi, Nankoku-shi, Osaka, Shizuoka, Suita-shi, and Yokohama, JapanSee the 17 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
- Has a test of your tumour shown a change (mutation) in the KRAS, NRAS or BRAF genes?
- Has a test shown that your tumour is 'MSI-high' or 'dMMR'?
- Which best describes how well you can look after yourself and be active?
Source: NCT07284849, who can take part
Where in Japan
- Hyogo Cancer CenterAkashi-shi, JapanTaking people
- Chiba Cancer CenterChiba, JapanTaking people
- National Cancer Center HospitalChūōku, JapanNot yet recruiting
- NHO Kyushu Cancer CenterFukuoka, JapanTaking people
- Saitama Medical University International Medical CenterHidaka-shi, JapanTaking people
- National Cancer Center Hospital EastKashiwa-shi, JapanTaking people
- St. Marianna University HospitalKawasaki-shi, JapanNot yet recruiting
- Kagawa University HospitalKita-gun, JapanTaking people
- Saitama Cancer CenterKitaadachi-gun, JapanNot yet recruiting
- Kobe City Hospital Organization Kobe City Medical Center General HospitalKobe, JapanTaking people
- Cancer Institute Hospital of JFCRKōtoku, JapanTaking people
- Kurashiki Central HospitalKurashiki-shi, JapanNot yet recruiting
- Kochi Medical School HospitalNankoku-shi, JapanTaking people
- Osaka International Cancer InstituteOsaka, JapanTaking people
- Shizuoka Cancer CenterShizuoka, JapanTaking people
- The University of Osaka HospitalSuita-shi, JapanTaking people
- Kanagawa Cancer CenterYokohama, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07284849EU 2025-523735-19-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.Read full original descriptionShow less
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Inclusion: Stage IV colorectal adenocarcinoma not amenable to curative resection; No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment; Measurable disease per RECIST v1.1; ECOG performance status of 0 or 1; Adequate organ function determined by laboratory results.
Exclusion: Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years; Significant concurrent and/or uncontrolled medical condition; History of other malignancy within 2 years; Active autoimmune disease that has required systemic treatment in the past 2 years; History of organ transplant, including allogeneic stem cell transplantation; Other protocol-defined inclusion/exclusion criteria apply; MSI-H/dMMR per historical data in the medical record; BRAF V600E mutation per historical data in the medical record; Untreated and/or progressing CNS metastases.